Oncology Hematology Care, Cincinnati
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06297226

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

TriHealth Cancer and Blood Institute, Cincinnati

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT07555938

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Cleveland

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07681596

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Gabrail Cancer & Research Center, Canton

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06087653

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Oncology Hematology Care Clinical Trials, LLC, Cincinnati
TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
Oncology Hematology Care Clinical Trials, LLC, Cincinnati
외 5개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Canton

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05714839

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

OhioHealth O'Bleness Hospital, Athens
Good Samaritan Hospital - Cincinnati, Cincinnati
Bethesda North Hospital, Cincinnati
외 15개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT04566328

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Ohio State University, Columbus

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Cleveland Clinic - Taussig Cancer Institute, Cleveland

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT05651932

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Cincinnati
Research Site, Cleveland
Research Site, Columbus
외 1개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 8. 12. 업데이트됨 · NCT07280013

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
The Ohio State University /ID# 271336, Columbus

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 7. 21. 업데이트됨 · NCT06892522

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

University Of Cincinnati Medical Center /ID# 251746, Cincinnati

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

The Ohio State University James Cancer Hospital, Columbus

피험자 모집 중1상

18세 이상 · 모든 성별 · 2026. 7. 8. 업데이트됨 · NCT05137054

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 7. 8. 업데이트됨 · NCT07657312

Integrated Cancer Repository for Cancer Research

Aultman Alliance Community Hospital, Alliance
Aultman Hospital, Canton

피험자 모집 중관찰 연구건강한 지원자 환영

19세 ~ 110세 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT02012699

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Indu and Raj Soin Medical Center, Beavercreek
Saint Elizabeth Boardman Hospital, Boardman
Dayton Physicians LLC-Miami Valley South, Centerville
외 17개

피험자 모집 중3상

전 연령 · 모든 성별 · 2026. 6. 10. 업데이트됨 · NCT05561387

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

The Ohio State University- The James Cancer Hospital and Solove Research Institute, Columbus

피험자 모집 중2상

19세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT06974786

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

University of Cincinnati, Cincinnati
Seidman Cancer Center-University Hospitals Cleveland Medical Center, Cleveland
Ohio State Medical Center, James Cancer Center, Columbus
외 1개

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05243797

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

The Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 6. 2. 업데이트됨 · NCT05145400

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중

18세 이상 · 모든 성별 · 2026. 5. 27. 업데이트됨 · NCT07609030

A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma

Study Site 104, Columbus

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 5. 12. 업데이트됨 · NCT07582432

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Cincinnati Children's Hospital Medical Center, Cincinnati
University of Cincinnati, Cincinnati
The Ohio State University, Columbus

피험자 모집 중1상

13세 이상 · 모든 성별 · 2026. 5. 5. 업데이트됨 · NCT04771572

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site, Columbus

피험자 모집 중3상

18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT06679101

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Oncology Hematology Care, Cincinnati

피험자 모집 중2상

18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT05972135

Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma

Ohio State University James Cancer Hospital, Columbus

피험자 모집 중1/2상

18세 이상 · 모든 성별 · 2026. 4. 20. 업데이트됨 · NCT03761108

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

The Ohio State University Comprehensive Cancer Center, Columbus

피험자 모집 중1/2상

12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555

ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.